Ovral L Tablet is a combined oral contraceptive containing Ethinyl Estradiol (0.03 mg) and Levonorgestrel (0.15 mg), indicated for the prevention of pregnancy. Ethinyl Estradiol, a synthetic estrogen, and Levonorgestrel, a synthetic progestin, work synergistically to inhibit ovulation, alter the cervical mucus to prevent sperm penetration, and modify the endometrial lining to reduce the likelihood of implantation. This dual-action mechanism ensures high contraceptive efficacy when taken as directed. Ovral L is typically administered orally once daily, preferably at the same time each day, starting on the first day of the menstrual cycle or as advised by a healthcare professional. It is essential to adhere strictly to the prescribed regimen to maintain contraceptive effectiveness. Besides contraception, Ovral L may also be prescribed for managing menstrual disorders such as dysmenorrhea, menorrhagia, or irregular cycles. Contraindications include a history of thromboembolic disorders, hormone-sensitive malignancies, uncontrolled hypertension, liver disease, and known hypersensitivity to any component. Common adverse effects may include nausea, breast tenderness, headache, and breakthrough bleeding. Patients should consult their healthcare provider before initiating therapy to evaluate individual risks and benefits and discuss potential drug interactions. Regular follow-up is recommended to monitor tolerance and efficacy.